Table 1.

Selected drugs targeting aberrant cell survival in diffuse B cell lymphoma.

Pathways	Targets	Drugs
BCR signaling	BTK	Ibrutinib, BGB-3111, acalabrutinib, TG-1701
	MALT1	Phenothiazines, MI-2
	PKC-β	Enzastaurin
	SYK	Fostamatinib, entospletinib, TAK-659
	PI3K	Copanlisib, buparlisib, CUDC-907, idelalisib, YY-20394, INCB050465, TGR-1202
	AKT	AZD5363, MK2206
	mTOR	Everolimus, temsirolimus
BCL2 family	BCL2	Navitoclax, venetoclax, obatoclax
	MCL1	S63845, AMG176
The p53 pathway	p53	APR-246
	MDM2	Nutlin-3a, idasanutlin
	MDM4	XI-011
	XPO1	Selinexor

BTK, Bruton tyrosine kinase; PKCβ, Protein kinase C β; SYK, spleen tyrosine kinase.